ArticlePLoS neglected tropical diseases2021
Control of cystic echinococcosis in the Middle Atlas, Morocco: Field evaluation of the EG95 vaccine in sheep and cesticide treatment in dogs.
Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Reinfection dynamics of owned dogs with Echinococcus granulosus sensu lato in endemic rural areas of central Iran: Implications for cystic echinococcosis control.PLoS neglected tropical diseases · 2026Article
- Community knowledge, attitudes and practices related to cystic echinococcosis in Ethiopia: Implications for control.One health (Amsterdam, Netherlands) · 2026Article
- Molecular characterization of Echinococcus species causing human cystic echinococcosis in Algeria: predominance of Echinococcus granulosus sensu stricto.Parasite (Paris, France) · 2026Article
- Modelling the Transmission Dynamics and Risk of Ovine Cystic Echinococcosis in Argentina Using the CEST Model (Cystic Echinococcosis Stochastic Transmission Model).Journal of parasitology research · 2026Article
- Optimization of echinococcosis control measures based on system dynamics.PLoS computational biology · 2025Article
- A tailored nanocarrier DMON and CpGs synergistically drive the formulation of a highly immunogenic and long-acting vaccine against echinococcosis.Materials today. Bio · 2025Article
- The Effect of Lamb Vaccination Against Echinococcosis on the Scale of Livestock Farming in Northwestern China.Veterinary medicine and science · 2025Article
- [Controlling cystic echinococcosis: outlook in the 21st centuryControle da equinococose/hidatidose cística: perspectivas no século XXI].Revista panamericana de salud publica = Pan American journal of public health · 2025Article
- miR-378a-5p targeting BRAF regulates CD4Frontiers in immunology · 2025Article
- Echinococcus granulosus sensu lato control measures: a specific focus on vaccines for both definitive and intermediate hosts.Parasites & vectors · 2024Review
- Ultrasonography screening of hepatic cystic echinococcosis in sheep flocks used for evaluating control progress in a remote mountain area of Hejing County, Xinjiang.BMC veterinary research · 2024Article
- An innovative strategy for deworming dogs in Mediterranean areas highly endemic for cystic echinococcosis.Parasites & vectors · 2024Article
- Cystic echinococcosis (Echinococcus granulosus sensu lato infection) in Tunisia, a One Health perspective for a future control programme.Parasite (Paris, France) · 2024Review
- Protective efficacy of six recombinant proteins as vaccine candidates against Echinococcus granulosus in dogs.PLoS neglected tropical diseases · 2023Article
- Ultrasonography of Parasitic Diseases in Domestic Animals: A Systematic Review.Animals : an open access journal from MDPI · 2022Review
- Identification of B-cell dominant epitopes in the recombinant protein P29 from Echinococcus granulosus.Immunity, inflammation and disease · 2022Article
- Chromosome-scale Echinococcus granulosus (genotype G1) genome reveals the Eg95 gene family and conservation of the EG95-vaccine molecule.Communications biology · 2022Article
- The RecombinantFrontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCystic echinococcosis (CE) is an important cause of human morbidity and mortality worldwide, particularly in Morocco and other North African countries. METHODOLOGY/PRINCIPAL
findingsWe investigated the potential of three strategies to reduce Echinococcus granulosus transmission: (1) 4-monthly treatment of dogs with praziquantel, (2) vaccination of sheep with the EG95 vaccine and (3) a combination of both measures. These measures were implemented during four consecutive years in different areas of the Middle Atlas Mountains in Morocco. The outcome of the interventions was assessed through hydatid cyst (viable and non-viable) counts in liver and lungs using necropsy or in vivo ultrasound examination of the liver. A total of 402 lambs were recruited for annual vaccination with the EG95 anti-E. granulosus vaccine and 395 similar lambs were selected as non-vaccinated controls. At approximately four years of age the relative risk (estimated as odds ratio) for vaccinated sheep to have viable hydatid cysts compared with non-vaccinated controls was 3% (9.37% of the vaccinated sheep were found infected while 72.82% of the controls were infected; p = 0.002). The number of viable cysts in vaccinated animals was reduced by approximately 97% (mean counts were 0.28 and 9.18 respectively; p<0.001). An average of 595 owned dogs received 4-monthly treatment during the 44 months trial, corresponding to 91% of the owned dog population. Approximately, 5% of them were examined for E. granulosus adult worms by arecoline purge or eggs in feces (confirmed by PCR). The proportion of infected dogs significantly decreased after treatment (12% versus 35%; p<0.001). Post-treatment incidence of re-infestation corresponded to a monthly risk of 4% (95% CI: 3-6%). Treatment of owned dogs on a 4-monthly basis did not reduce the level of transmission of E. granulosus to sheep, nor did it enhance the level of control generated by vaccination of sheep with EG95, possibly because of unowned dogs and wild canids were not treated. CONCLUSIONS/SIGNIFICANCE: These data suggest that vaccination of sheep with EG95 has the potential to reduce the level of CE in Morocco and in other parts of the world with similar transmission dynamics. Under the epidemiological circumstances existing in the trial area, 4-monthly treatment of owned dogs with praziquantel was insufficient to have a major impact of E. granulosus transmission to sheep.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.